The first minutes after a heart attack are a race against biology, a contest often lost in the distance to a hospital. For a team of founders in Dehradun, that distance became the core of a hardware bet: a portable, smartphone-connected 12-lead ECG device that could turn any clinic, ambulance, or village health center into a cardiac assessment post. Eight years on, Sunfox Technologies has deployed approximately 60,000 of its Spandan devices across India, reaching more than 20,000 villages, according to company reports from October 2026 [Economic Times - ET Entrepreneur, October 2026]. The company recently secured a $7 million Series A round, led by investors including Ashish Kacholia and Alchemy Capital, to fuel its next phase of expansion and research [Economic Times - ET Entrepreneur, October 2026]. For Pulse Raman, the story is less about the gadget and more about the patient pathway it aims to redefine, bringing a foundational diagnostic tool out of the cardiology lab and into the places where people first feel chest pain.
The hardware wedge into rural care
Spandan's clinical premise is straightforward. It is a compact hardware unit that connects to a smartphone via Bluetooth or audio jack, guiding a user through placing electrodes to capture a 12-lead electrocardiogram. The reading is displayed and stored on the phone, where it can be shared with a remote physician for interpretation. The company claims the process takes under two minutes [Sunfox Technologies]. This portability targets a critical gap in cardiac care infrastructure, particularly in tier-2 and tier-3 cities and rural India where access to full-scale ECG machines and specialists is limited. The device is marketed across a spectrum from personal home monitoring to clinical, hospital, and public-health program use [YourStory].
Peer-reviewed validation adds weight to the commercial claims. A cross-sectional observational study published in Cardiology Research found that the Spandan Pro ECG demonstrated "comparable accuracy with the gold standard 12-lead ECG for the diagnosis of ST elevation" and helped in making clinical decisions for percutaneous coronary intervention (PCI), a life-saving procedure for heart attacks [Validation of Decisions for Percutaneous Coronary Intervention Using Smartphone-Based Electrocardiogram Device Spandan: A Cross-Sectional Observational Study - PMC]. This kind of evidence is crucial for adoption in formal healthcare settings and for building trust among medical professionals.
A funding journey from Sharks to Series A
Sunfox's path has been a steady build, supported by a mix of celebrity angel investors and institutional capital. The company's founding in 2016 is attributed by founders to a personal motivation following the loss of a friend, focusing on improving cardiac assessment speed [Economic Times - ET Entrepreneur, October 2026]. Its early public break came in 2022 with an appearance on Shark Tank India, where it secured investment from Namita Thapar, Peyush Bansal, Anupam Mittal, Vineeta Singh, and Ghazal Alagh [Whiteford Research company profile]. Subsequent rounds brought in strategic support for deployment, including from the SAMRIDH blended finance facility in 2023 to strengthen technical and sales teams for public-health facility rollouts [SAMRIDH]. A pre-Series round in August 2024, led by Venture Catalysts, added approximately $1.8 million (₹15 crore) to the war chest [ThePrint, August 2024]. The recent $7 million Series A marks a significant step-up, intended to fund Indian expansion, international go-to-market, organizational scaling, and continued R&D [Economic Times - ET Entrepreneur, October 2026].
| Metric | Value |
|---|---|
| Jan 2022 Seed | 0.12 M USD (est.) |
| Mar 2023 Seed | n/a M USD |
| Aug 2024 Seed | 1.8 M USD |
| Oct 2026 Series A | 7 M USD |
The founders building beyond software
The founding team brings a blend of hardware, software, and business development experience, somewhat atypical for a pure-play digital health startup. The company was founded by Rajat Jain, Arpit Jain, Sabit Rawat, Nitin Chandola, and Saurabh Badola [VCCircle]. Rajat Jain is listed as the CEO, while Nitin Chandola leads hardware R&D and Saurabh Badola heads software R&D and product [ZoomInfo] [Saurabh Badola - Sunfox Technologies Pvt. Ltd. | LinkedIn]. Sabit Rawat leads marketing and sales [Sabit Rawat on LinkedIn]. This multi-disciplinary co-founding structure suggests a hands-on approach to the integrated hardware-software challenge, a necessity for a regulated medical device company.
Scaling a physical footprint
The most tangible metric of Sunfox's traction is its deployment footprint. The claim of 60,000 devices across India, touching over 20,000 villages, points to a distribution strategy deeply enmeshed with public health initiatives and grassroots healthcare networks [Economic Times - ET Entrepreneur, October 2026]. This scale is not merely a sales number; it represents an installed base that generates recurring revenue through disposable electrodes and potential software subscriptions, while also creating a network effect for telemedicine services. The company has also reported users in 20 countries, indicating early international interest [Sunfox Technologies, August 2024].
The road ahead and the risks
For all its momentum, Sunfox's journey faces the complex realities of medtech. The company must navigate:
- Regulatory expansion. Each new target market, whether in South Asia or beyond, requires its own regulatory clearance (like FDA 510(k) or CE Mark). Progress here is non-negotiable for clinical sales.
- Clinical workflow integration. Device adoption requires training and buy-in from healthcare workers. Sustaining engagement and proving impact on patient outcomes in real-world settings is an ongoing challenge.
- Competitive evolution. While no direct competitors are named in sources, the landscape for portable cardiac monitors includes large incumbent device makers and a growing field of digital health startups. Sunfox's moat rests on its specific form factor, accuracy validation, and deep distribution in hard-to-reach areas.
The company's answer to these challenges appears to be a focus on deepening its clinical evidence, as seen with the PCI study, and leveraging its Series A capital to build out its commercial and regulatory teams for broader market entry.
The standard of care, redefined
The ambition behind Spandan is clearest when viewed against the current standard of care for acute coronary syndrome in remote regions. Today, a patient experiencing chest pain in a village may face hours of travel to a facility with a functioning ECG machine. The diagnostic delay can mean the difference between a treated heart attack and a fatal one. By placing a validated 12-lead ECG in the hands of a community health worker, Sunfox is attempting to collapse that timeline. The device is aimed at the vast patient population in peri-urban and rural areas who are at high risk for cardiovascular disease but historically underserved by diagnostic infrastructure. The next twelve months will test whether the company can convert its impressive village-level footprint into sustainable commercial growth and, more importantly, a measurable impact on cardiac emergency response rates across India and eventually in new international markets.
Sources
- [Economic Times - ET Entrepreneur, October 2026] Sunfox Technologies raises $7 mn series A funding | https://entrepreneur.economictimes.indiatimes.com/news/funding/sunfox-technologies-raises-7-mn-series-a-funding/134756483
- [Sunfox Technologies] Spandan Portable 12-Lead ECG | https://www.sunfox.in/
- [YourStory, October 2026] Medtech company Sunfox Technologies raises $7M to scale cardiac diagnostics platform | https://yourstory.com/2026/10/medtech-company-sunfox-technologies-raises-7m
- [Validation of Decisions for Percutaneous Coronary Intervention Using Smartphone-Based Electrocardiogram Device Spandan: A Cross-Sectional Observational Study - PMC] Validation of Decisions for Percutaneous Coronary Intervention Using Smartphone-Based Electrocardiogram Device Spandan: A Cross-Sectional Observational Study | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11194568/
- [Whiteford Research company profile] Sunfox Technologies profile | https://biobase.whitefordresearch.com/companies/sunfox
- [SAMRIDH] SAMRIDH support for Sunfox Technologies | https://www.samridhimpact.com/sunfox/
- [ThePrint, August 2024] Sunfox Technologies secures additional Rs 15 crore in pre-Series funding to scale global cardiac innovations | https://theprint.in/ani-press-releases/sunfox-secures-additional-rs-15-crore-in-pre-series-funding-to-scale-global-cardiac-innovations/2243717/
- [VCCircle] Sunfox Technologies | https://www.vccircle.com/bytexlsunfox-technologies-zomint-others-pocket-early-stage-cheques
- [ZoomInfo] Sunfox Technologies team data | https://www.zoominfo.com/c/sunfox-technologies-pvt-ltd/512894157
- [Saurabh Badola - Sunfox Technologies Pvt. Ltd. | LinkedIn] Saurabh Badola profile | https://www.linkedin.com/in/saurabhbadola
- [Sabit Rawat on LinkedIn] Sabit Rawat profile | https://www.linkedin.com/in/sabit-rawat-2b56b1146